4,4'-Methylenebis(2-chloroaniline) (MOCA)

MOCA was developed in the 1950s as a curing agent for polyurethane elastomers that offered better physical properties than earlier amine curatives [1]. Cast polyurethane using MOCA produces very tough, wear-resistant elastomers used in wheels, rollers, seals, mining equipment liners, and industrial flooring [2]. MOCA is liquid at room temperature, facilitating mixing with polyurethane prepolymers — but this same liquid state means it contacts workers' skin during mixing operations [1]. OSHA regulates it under 29 CFR 1910.1014 as a carcinogen after bladder tumor clusters were documented in polyurethane casting workers [2].

Workers mixing and casting MOCA-cured polyurethane elastomers face dermal and inhalation exposure [1]. MOCA is readily absorbed through skin — dermal absorption is considered the primary route in many industrial scenarios [2]. Heating MOCA (as required for some casting operations) increases vapor generation and inhalation exposure [1].

MOCA is metabolically N-hydroxylated to reactive intermediates that form bladder DNA adducts in exactly the same mechanism as benzidine and 4-aminobiphenyl [1]. Animal studies showed bladder tumors in all species tested. OSHA regulated it before definitive human epidemiological proof — subsequent worker studies confirmed bladder cancer in MOCA-exposed polyurethane workers [2]. EPA B2 probable carcinogen; OSHA regulated carcinogen [1].

Polyurethane elastomer casting workers represent the primary at-risk population [1]. MOCA use is widespread in industrial applications globally [2].

1. Use closed mixing systems and local exhaust ventilation to minimize MOCA vapor and skin contact [1]. 2. OSHA requires: engineering controls, medical surveillance including urine cytology, and biological monitoring [2]. 3. Wear impermeable gloves (butyl rubber preferred) and chemical-resistant apron [1]. 4. Bladder cancer surveillance for all workers with past MOCA exposure [2].